Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Prostatic Neoplasms 5Carcinoma, Hepatocellular 4Parathyroid Neoplasms 2Multiple Endocrine Neoplasia Type 1 1Liver Diseases 1Hyperparathyroidism, Primary 1Disease 1Breast Neoplasms 1

Interventions

Sorafenib 5Blood Specimen Collection 4lenvatinib 3sintilimab 2pembrolizumab 2ledipasvir, sofosbuvir drug combination 2halofantrine 2camrelizumab 2atezolizumab 2Liver Transplantation 2Immunotherapy 2Control Groups 2Bevacizumab 2Antibodies 2veliparib 1trifluridine tipiracil drug combination 1trametinib 1toripalimab 1titanium silicide 1tislelizumab 1rubitecan 1repotrectinib 1pevonedistat 1ozanimod 1linifanib 1genexol-PM 1gadolinium ethoxybenzyl DTPA 1fluorocholine 1fisogatinib 1ficlatuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Liver Diseases × fluorocholine × Clear all
NCT02074202 2014-02-28

To Evaluate the Efficacy and Safety of (18F-FCH) Comparing With (18F-FDG) for Detecting Hepatocellular Carcinoma

National Taiwan University Hospital

Phase 3 Unknown
150 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡